clinicalomicsprowebdirectory
News
Topics
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Magazine
Marketplace
Multimedia
Webinars
eBooks
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Search
Advertise
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Lead Generation Campaigns
Email Nurture Campaigns
Custom Content Solutions
About Us
Contact Us
Mary Ann Liebert Publishers
Create a Free Account
Log In
Clinical OMICs – Molecular Diagnostics in Precision Medicine
News
Coronavirus
Pfizer, BioNTech COVID-19 Vaccine Construct Shows Promising Phase I/II Data
Bioinformatics
NIH to Provide $75M to Increase Diversity in Its eMERGE Network
Translational Research
Promising New Liver Disease Diagnostic Analyzes Microbiome from Stool Samples
Precision Medicine
Genome Medical Raises $14M in Series B Financing
Precision Medicine
Sherlock, binx health Partner on CRISPR-Based, Point-of-Care COVID-19 Test
Topics
All
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Coronavirus
Pfizer, BioNTech COVID-19 Vaccine Construct Shows Promising Phase I/II Data
Bioinformatics
NIH to Provide $75M to Increase Diversity in Its eMERGE Network
Translational Research
Promising New Liver Disease Diagnostic Analyzes Microbiome from Stool Samples
Precision Medicine
Genome Medical Raises $14M in Series B Financing
Magazine
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 3
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 2
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 1
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 6
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 5
Marketplace
Multimedia
All
Webinars
eBooks
Upcoming Webinars
Integrating NGS and Optical Mapping to Resolve Focal Amplifications in Cancer
On Demand Webinars
Newborn Genomic Screening: In Sickness and In Health
eBooks
Clinical Research in a Real-Time Sequencing Age
Precision Medicine
From Bench to Clinic—The Potential of New Sequencing Tools
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Home
Companies
Cancer Genetics
Cancer Genetics
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Cancer Genetics
Foundation Medicine Eyes Liquid Biopsy Expansion, DNA Methylation Adoption, with Lexent...
June 12, 2020
Cancer Genetics
Interpace Diagnostics Buys Cancer Genetics’ BioPharma Business for $23.5M
July 17, 2019
Cancer Genetics
Cancer Genetics Scraps Planned Merger with NovellusDx
December 17, 2018
Cancer Genetics
Cancer Genetics CEO Panna Sharma Steps Down
February 5, 2018
Cancer Genetics
Cancer Genetics Gains $1.1M from NJ Net Operating Loss Program
December 28, 2017
Cancer Genetics
Third Quarter Brings Record Revenue for Cancer Genetics
November 9, 2017
Cancer Genetics
Cancer Genetics to Offer Biomarker Services for eFFECTOR Therapeutics Lead Candidate
April 10, 2017
Cancer Genetics
Ignyta to Use Angsana Cancer Panel in Registrational Trial of Anti-Tumor...
March 3, 2017
Cancer Genetics
Philips Expands Personalized Cancer Collaboration with NYMC
December 7, 2016
Cancer Genetics
University of Michigan Taps Tempus to Commercialize MI-ONCOSEQ Cancer Panel
October 12, 2016
Load more
Scroll Up
We use cookies to give you a better experience on clinicalomics.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
![Cancer Genetics (CGI) has terminated its planned merger with NovellusDx and will instead “pursue alternative strategic and financial transactions” intended to enhance shareholder value.. [nicolas_ / Getty Imagesnicolas_ / Getty Images]](https://www.clinicalomics.com/wp-content/uploads/2019/01/2051-324x160.jpeg "Cancer Genetics Scraps Planned Merger with NovellusDx")
![Cancer Genetics (CGI) has received $1.1 million in net cash proceeds through the transfer of tax credits approved by the New Jersey Technology Business Tax Certificate Transfer (NOL) program of the New Jersey Economic Development Authority (NJEDA). [Source: Maxim_Kazmin/Fotolia]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1407-324x160.jpeg "Cancer Genetics Gains $1.1M from NJ Net Operating Loss Program")
